Introduction
In our initial characterization of mice lacking Fibroblast Growth Factor 14 (FGF14) (Wang et al., 2002) , we described existing sensorimotor impairments, ataxia and a paroxysmal hyperkinetic movement disorder. This analysis led directly to the identification of mutations in FGF14 (Brusse et al., 2006; Dalski et al., 2005; Van Swieten et al., 2003) in which affected individuals exhibited a slowly progressive onset of tremors, dyskinesia, and ataxia that were strikingly similar to the phenotype of Fgf14 −/− mice. Importantly, these patients also exhibited impaired cognitive capabilities, suggesting that FGF14 may play a role in mediating certain cognitive functions. These findings in humans prompted us to examine the learning and memory capabilities and other behaviors in
FGF14 is a member of the FGF homologous factors subfamily (FHF1-4), and is also known as FHF4. It is expressed in similar brain regions in mice and humans, including the hippocampal CA (Cornu Ammons) subfields, cerebral cortex (temporal lobe), putamen, and pyramidal cell layer of the hippocampus (Wang et al., 2002) . Although the complete functions of FGF14 are not known, evidence is beginning to suggest an important role in CNS neuronal physiology (Munoz-Sanjuan et al., 2000; Smallwood et al., 1996; Wang et al., 2002; Yamamoto et al., 1998) . Recent work showed that FGF14 could modulate the electrophysiological functions of neurons by modulating voltage-gated sodium (Nav) channel activity (Lou et al., 2005) . Furthermore, we found that synaptic transmission at hippocampal Schaffer collateral-CA1 synapses and short and long term modulation are impaired in Fgf14 −/− mice (Xiao et al., in press).
Fgf14
−/− mice were also observed to have decreased numbers of synaptic vesicles docked at presynaptic CA1 synapses, a significant synaptic fatigue/depression during high/low-frequency stimulation and a reduction in mEPSC frequency, but not amplitude, in cultured hippocampal neurons (Xiao et al., in press 
